Indicated for: cancer
Route of administration: oral
Substance: nintedanib (antineoplastic agent)
ATC: L01EX09 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors)
Nintedanib is a medication used for the treatment of idiopathic pulmonary fibrosis and other progressive interstitial lung diseases. It is a tyrosine kinase inhibitor that works by reducing inflammation and fibrosis in the lungs.
The medication is taken orally, usually twice daily with meals. The dose is adjusted based on the patient's tolerance and any adverse reactions. Common side effects include diarrhea, nausea, vomiting, and decreased appetite.
Nintedanib is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with severe liver impairment.
This medication is an important option for patients with progressive lung diseases, helping to slow disease progression and improve their quality of life.
NHP 6.20 (C2) - Idiopathic pulmonary fibrosis
Price
Copayment
Patient
3769.83 RON
3769.83 RON
0.00 RON